Galectin-9 in autoimmune hepatitis: Correlation between serum levels of galectin-9 and M2BPGi in patients with autoimmune hepatitis

Naoki Matsuoka,Hideko Kozuru,Tomohiro Koga,Seigo Abiru,Kazumi Yamasaki,Atsumasa Komori,Yuya Fujita,Junpei Tenmoku,Tomoyuki Asano,Shuzo Sato,Eiji Suzuki,Makiko Yashiro Furuya,Hiroko Kobayashi,Hiroshi Watanabe,Atsushi Naganuma,Kaname Yoshizawa,Masaaki Shimada,Keisuke Ario,Haruhiro Yamashita,Hiroshi Kohno,Toshihiko Kaneyoshi,Minoru Nakamura,Hiroshi Furukawa,Atsushi Takahashi,Atsushi Kawakami,Hiromasa Ohira,Hiroshi Yatsuhashi,Kiyoshi Migita

Galectin-9 in autoimmune hepatitis: Correlation between serum levels of galectin-9 and M2BPGi in patients with autoimmune hepatitis

2019

AbstractAutoimmune hepatitis (AIH) is a disorder of unknown etiology in which immune-mediated liver damage progresses to cirrhosis or hepatocellular carcinoma (HCC). The mainstay therapy for AIH is steroids and other immunosuppressive treatments. Currently, there are no validated markers for monitor

Keywords:

Gastroenterology
Internal medicine
Cirrhosis
Etiology
Diabetes mellitus
Medicine
Autoimmune hepatitis
Hepatocellular carcinoma
Galectin
Hepatitis
Physical therapy
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations